These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 25132656

  • 1. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
    Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, Stiemerling E, Poitras N, Lorey T, Kinney W.
    Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL, Chen W, Lei XQ, Qin Y, Wu ZN, Pan QJ, Zhang X, Chang BF, Zhang SK, Guo HQ, Qiao YL.
    Oncotarget; 2016 Apr 19; 7(16):21181-9. PubMed ID: 27029033
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.
    Waldstrøm M, Christensen RK, Ørnskov D.
    Cancer Cytopathol; 2013 Mar 19; 121(3):136-45. PubMed ID: 22987560
    [Abstract] [Full Text] [Related]

  • 4. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
    Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R, PALMS Study Group.
    J Natl Cancer Inst; 2013 Oct 16; 105(20):1550-7. PubMed ID: 24096620
    [Abstract] [Full Text] [Related]

  • 5. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GA, Ridder R, Snijders PJ, Meijer CJ.
    Int J Cancer; 2015 May 15; 136(10):2361-8. PubMed ID: 25345358
    [Abstract] [Full Text] [Related]

  • 6. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.
    Solares C, Velasco J, Álvarez-Ruiz E, González-Fernández L, Encinas AI, Astudillo A, Schneider J.
    Anticancer Res; 2015 Nov 15; 35(11):6291-5. PubMed ID: 26504065
    [Abstract] [Full Text] [Related]

  • 7. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
    Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R.
    Gynecol Oncol; 2011 Jun 01; 121(3):505-9. PubMed ID: 21420158
    [Abstract] [Full Text] [Related]

  • 8. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
    Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, Alameda F, Keller T, Rehm S, Ridder R, PALMS Study Group.
    Cancer Cytopathol; 2015 Jun 01; 123(6):373-81. PubMed ID: 25891096
    [Abstract] [Full Text] [Related]

  • 9. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M, Gotlieb W, Gilbert L, Hemmings R, Behr MA, Franco EL, STAIN-IT Study Group.
    Int J Cancer; 2021 Jan 15; 148(2):492-501. PubMed ID: 32781481
    [Abstract] [Full Text] [Related]

  • 10. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
    Liu W, Gong J, Xu H, Zhang D, Xia N, Li H, Song K, Lv T, Chen Y, Diao Y, Jao J, Dai S, Zhao P, Yao Q.
    Diagn Cytopathol; 2020 Jul 15; 48(7):635-644. PubMed ID: 32275355
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY, Lim KL, Hilmy MH, Thike AA, Goh ST, Song LH, Hwang JSG, Mantoo S.
    Malays J Pathol; 2017 Dec 15; 39(3):257-265. PubMed ID: 29279588
    [Abstract] [Full Text] [Related]

  • 12. Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population.
    Benevolo M, Mancuso P, Allia E, Gustinucci D, Bulletti S, Cesarini E, Carozzi FM, Confortini M, Bisanzi S, Rubino T, Rollo F, Marchi N, Farruggio A, Pusiol T, Venturelli F, Giorgi Rossi P, New Technologies for Cervical Cancer 2 (NTCC2) Working Group.
    Cancer Cytopathol; 2021 May 15; 129(5):383-393. PubMed ID: 33142029
    [Abstract] [Full Text] [Related]

  • 13. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH, Witte BI, Van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, Balfoort-van der Meij GA, Bleeker MC, Snijders PJ, Meijer CJ.
    Br J Cancer; 2014 Mar 18; 110(6):1579-86. PubMed ID: 24518601
    [Abstract] [Full Text] [Related]

  • 14. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT, Dalen I, Hansen E, Loge JL, Dybdahl BM, Dirdal MB, Moltu P, Berland JM.
    Cancer Cytopathol; 2017 Apr 18; 125(4):283-291. PubMed ID: 27918650
    [Abstract] [Full Text] [Related]

  • 15. Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.
    Koo YJ, Hahn HS, Lee IH, Lim KT, Lee KH, Kim HS, Kim TJ, Chun YK, Kim HS, Hong SR.
    Virchows Arch; 2013 Nov 18; 463(5):689-96. PubMed ID: 24081504
    [Abstract] [Full Text] [Related]

  • 16. Interlaboratory concordance of p16/Ki-67 dual-staining interpretation in HPV-positive women in a screening population.
    Benevolo M, Mancuso P, Allia E, Gustinucci D, Bulletti S, Cesarini E, Carozzi FM, Confortini M, Bisanzi S, Carlinfante G, Rubino T, Rollo F, Marchi N, Farruggio A, Pusiol T, Venturelli F, Giorgi Rossi P, New Technologies for Cervical Cancer 2 Working Group.
    Cancer Cytopathol; 2020 May 18; 128(5):323-332. PubMed ID: 32168431
    [Abstract] [Full Text] [Related]

  • 17. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL, Schiffman M.
    Clin Cancer Res; 2012 Aug 01; 18(15):4154-62. PubMed ID: 22675168
    [Abstract] [Full Text] [Related]

  • 18. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study.
    Schmidt D, Bergeron C, Denton KJ, Ridder R, European CINtec Cytology Study Group.
    Cancer Cytopathol; 2011 Jun 25; 119(3):158-66. PubMed ID: 21442767
    [Abstract] [Full Text] [Related]

  • 19. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
    Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N.
    JAMA Oncol; 2019 Feb 01; 5(2):181-186. PubMed ID: 30325982
    [Abstract] [Full Text] [Related]

  • 20. Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Polman NJ, Uijterwaal MH, Witte BI, Berkhof J, van Kemenade FJ, Spruijt JW, van Baal WM, Graziosi PG, van Dijken DK, Verheijen RH, Helmerhorst TJ, Steenbergen RD, Heideman DA, Ridder R, Snijders PJ, Meijer CJ.
    Int J Cancer; 2017 Jan 15; 140(2):423-430. PubMed ID: 27677098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.